Plow­ing ahead af­ter its lat­est set­back, Ax­o­vant nabs two as­sets to beef up gene ther­a­py pipeline

Fresh from the spec­tac­u­lar fail­ure of its de­men­tia drug, nelotanserin, which has been pushed to the scrap heap along with its much-hyped Alzheimer’s as­set, Ax­o­vant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.